COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02414854




Registration number
NCT02414854
Ethics application status
Date submitted
8/04/2015
Date registered
13/04/2015
Date last updated
23/10/2018

Titles & IDs
Public title
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Scientific title
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Secondary ID [1] 0 0
2014-004940-36
Secondary ID [2] 0 0
EFC13579
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dupilumab
Treatment: Drugs - Placebo
Treatment: Drugs - Inhaled corticosteroid (ICS) therapy
Treatment: Drugs - Albuterol/Salbutamol
Treatment: Drugs - Levalbuterol/Levosalbutamol

Placebo Comparator: Placebo (for Dupilumab 200 mg) q2w - 2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

Experimental: Dupilumab 200 mg q2w - 2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

Placebo Comparator: Placebo (for Dupilumab 300 mg) q2w - 2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

Experimental: Dupilumab 300 mg q2w - 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.


Treatment: Drugs: Dupilumab
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Treatment: Drugs: Placebo
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Treatment: Drugs: Inhaled corticosteroid (ICS) therapy
Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

Treatment: Drugs: Albuterol/Salbutamol
Oral inhalation as needed

Treatment: Drugs: Levalbuterol/Levosalbutamol
Oral inhalation as needed

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [1] 0 0
Baseline to Week 52
Primary outcome [2] 0 0
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [2] 0 0
Baseline, Week 12
Secondary outcome [1] 0 0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [1] 0 0
Baseline, Week 12
Secondary outcome [2] 0 0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [2] 0 0
Baseline to Week 52
Secondary outcome [3] 0 0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [3] 0 0
Baseline, Week 12
Secondary outcome [4] 0 0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [4] 0 0
Baseline to Week 52
Secondary outcome [5] 0 0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [5] 0 0
Baseline, Week 12
Secondary outcome [6] 0 0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [6] 0 0
Baseline to Week 52
Secondary outcome [7] 0 0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [7] 0 0
Baseline to Week 52
Secondary outcome [8] 0 0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [8] 0 0
Baseline, Week 12
Secondary outcome [9] 0 0
Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population - The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Timepoint [9] 0 0
Baseline, Week 24
Secondary outcome [10] 0 0
Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L - The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Timepoint [10] 0 0
Baseline, Week 24
Secondary outcome [11] 0 0
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population - The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Timepoint [11] 0 0
Baseline, Week 24
Secondary outcome [12] 0 0
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population - A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [12] 0 0
Baseline to Week 52
Secondary outcome [13] 0 0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [13] 0 0
Baseline, Week 12
Secondary outcome [14] 0 0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [14] 0 0
Baseline, Week 12
Secondary outcome [15] 0 0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [15] 0 0
Baseline, Week 12
Secondary outcome [16] 0 0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [16] 0 0
Baseline, Week 12
Secondary outcome [17] 0 0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [17] 0 0
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Secondary outcome [18] 0 0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [18] 0 0
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Secondary outcome [19] 0 0
Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [19] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [20] 0 0
Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
Timepoint [20] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [21] 0 0
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.
Timepoint [21] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [22] 0 0
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.
Timepoint [22] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [23] 0 0
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Timepoint [23] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [24] 0 0
Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population - LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Timepoint [24] 0 0
Baseline to Week 52
Secondary outcome [25] 0 0
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population - The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.
Timepoint [25] 0 0
Baseline up to Week 52
Secondary outcome [26] 0 0
Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population - The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.
Timepoint [26] 0 0
Baseline up to Week 52
Secondary outcome [27] 0 0
Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population - The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Timepoint [27] 0 0
Baseline, Weeks 2, 4, 8, 12, 36, and 52
Secondary outcome [28] 0 0
Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Timepoint [28] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [29] 0 0
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Timepoint [29] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [30] 0 0
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Timepoint [30] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [31] 0 0
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
Timepoint [31] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [32] 0 0
Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population - Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.
Timepoint [32] 0 0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Secondary outcome [33] 0 0
Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population - The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Timepoint [33] 0 0
Baseline, Weeks 12, 36, and 52
Secondary outcome [34] 0 0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population - EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
Timepoint [34] 0 0
Baseline, Weeks 12, 24, 36, and 52
Secondary outcome [35] 0 0
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population - The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
Timepoint [35] 0 0
Baseline, Weeks 12, 24, 36, and 52
Secondary outcome [36] 0 0
Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis - The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
Timepoint [36] 0 0
Baseline, Weeks 12, 24, 36, and 52
Secondary outcome [37] 0 0
Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis - RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).
Timepoint [37] 0 0
Baseline, Weeks 12, 24, 36, and 52

Eligibility
Key inclusion criteria
Inclusion criteria:

-Adults and adolescent participants with a physician diagnosis of asthma for =12 months,
based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following
criteria:

a) Existing treatment with medium to high dose ICS (=250 mcg of fluticasone propionate
twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone
propionate or equivalent) in combination with a second controller (eg, long-acting beta
agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose =1 month
prior to Visit 1.

i) Note for Japan: for participants aged 18 years and older, ICS must be on =200 mcg of
fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS
must be =100 mcg of fluticasone propionate twice daily or equivalent).

ii) Participants requiring a third controller for their asthma will be considered eligible
for this study, and it should also be used for at least 3 months with a stable dose =1
month prior to Visit 1.
Minimum age
12 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Participants <12 years of age or the minimum legal age for adolescents in the country
of the investigative site, whichever is higher (For those countries where local
regulations permit enrollment of adults only, participant recruitment will be
restricted to those who are =18 years of age).

- Weight is less than 30 kilograms.

- Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary
fibrosis, Churg-Strauss Syndrome, etc) which may impair lung function.

- A participant who experiences a severe asthma exacerbation (defined as a deterioration
of asthma that results in emergency treatment, hospitalization due to asthma, or
treatment with systemic steroids at any time from 1 month prior to the Screening Visit
up to and including the Baseline Visit).

- Evidence of lung disease(s) other than asthma, either clinical evidence or imaging
(Chest X-ray, CT, MRI) within 12 months of Visit 1 or at the screening visit, as per
local standard of care.

- Note for Japan: According to the request from the health authority, chest X-ray should
be performed at screening visit if there is no chest imaging (Chest X-ray, computed
tomography [CT], magnetic resonance imaging [MRI]) available within 3 months prior to
screening to exclude participants with suspected active or untreated latent
tuberculosis.

- Current smoker or cessation of smoking within 6 months prior to Visit 1.

- Previous smoker with a smoking history >10 pack-years.

- Comorbid disease that might interfere with the evaluation of Investigational Medicinal
Product.

The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigational Site Number 036005 - Campbelltown
Recruitment hospital [2] 0 0
Investigational Site Number 036001 - Clayton
Recruitment hospital [3] 0 0
Investigational Site Number 036002 - Frankston
Recruitment hospital [4] 0 0
Investigational Site Number 036006 - Glen Osmond
Recruitment hospital [5] 0 0
Investigational Site Number 036003 - Murdoch
Recruitment hospital [6] 0 0
Investigational Site Number 036004 - Parkville
Recruitment postcode(s) [1] 0 0
2560 - Campbelltown
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
5064 - Glen Osmond
Recruitment postcode(s) [5] 0 0
6150 - Murdoch
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Vermont
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
Argentina
State/province [34] 0 0
Bahia Blanca
Country [35] 0 0
Argentina
State/province [35] 0 0
Buenos Aires
Country [36] 0 0
Argentina
State/province [36] 0 0
Caba
Country [37] 0 0
Argentina
State/province [37] 0 0
Capital Federal
Country [38] 0 0
Argentina
State/province [38] 0 0
La Plata
Country [39] 0 0
Argentina
State/province [39] 0 0
Rosario
Country [40] 0 0
Argentina
State/province [40] 0 0
San Miguel De Tucuman
Country [41] 0 0
Argentina
State/province [41] 0 0
San Miguel De Tucumán
Country [42] 0 0
Brazil
State/province [42] 0 0
Florianópolis
Country [43] 0 0
Brazil
State/province [43] 0 0
Porto Alegre
Country [44] 0 0
Brazil
State/province [44] 0 0
Salvador
Country [45] 0 0
Brazil
State/province [45] 0 0
Sao Paulo
Country [46] 0 0
Brazil
State/province [46] 0 0
Sorocaba
Country [47] 0 0
Brazil
State/province [47] 0 0
São Bernardo Do Campo
Country [48] 0 0
Canada
State/province [48] 0 0
Burlington
Country [49] 0 0
Canada
State/province [49] 0 0
Calgary
Country [50] 0 0
Canada
State/province [50] 0 0
Mississauga
Country [51] 0 0
Canada
State/province [51] 0 0
Montreal
Country [52] 0 0
Canada
State/province [52] 0 0
Ottawa
Country [53] 0 0
Canada
State/province [53] 0 0
Quebec
Country [54] 0 0
Canada
State/province [54] 0 0
Sherbrooke
Country [55] 0 0
Canada
State/province [55] 0 0
Toronto
Country [56] 0 0
Canada
State/province [56] 0 0
Trois-Rivieres
Country [57] 0 0
Canada
State/province [57] 0 0
Vancouver
Country [58] 0 0
Chile
State/province [58] 0 0
Concepción
Country [59] 0 0
Chile
State/province [59] 0 0
Quillota
Country [60] 0 0
Chile
State/province [60] 0 0
Santiago
Country [61] 0 0
Chile
State/province [61] 0 0
Talcahuano
Country [62] 0 0
Chile
State/province [62] 0 0
Talca
Country [63] 0 0
Chile
State/province [63] 0 0
Temuco
Country [64] 0 0
Chile
State/province [64] 0 0
Valdivia
Country [65] 0 0
Chile
State/province [65] 0 0
Viña Del Mar
Country [66] 0 0
Colombia
State/province [66] 0 0
Bogota
Country [67] 0 0
Colombia
State/province [67] 0 0
Bogotá
Country [68] 0 0
France
State/province [68] 0 0
Brest
Country [69] 0 0
France
State/province [69] 0 0
Lille Cedex
Country [70] 0 0
France
State/province [70] 0 0
Lille
Country [71] 0 0
France
State/province [71] 0 0
Lyon
Country [72] 0 0
France
State/province [72] 0 0
Marseille
Country [73] 0 0
France
State/province [73] 0 0
Montpellier
Country [74] 0 0
France
State/province [74] 0 0
Nantes Cedex 1
Country [75] 0 0
France
State/province [75] 0 0
Paris
Country [76] 0 0
France
State/province [76] 0 0
Strasbourg
Country [77] 0 0
France
State/province [77] 0 0
Vandoeuvre-Les-Nancy
Country [78] 0 0
Germany
State/province [78] 0 0
Berlin
Country [79] 0 0
Germany
State/province [79] 0 0
Bochum
Country [80] 0 0
Germany
State/province [80] 0 0
Frankfurt Am Main
Country [81] 0 0
Germany
State/province [81] 0 0
Hannover
Country [82] 0 0
Germany
State/province [82] 0 0
Koblenz
Country [83] 0 0
Germany
State/province [83] 0 0
Lübeck
Country [84] 0 0
Germany
State/province [84] 0 0
Mainz
Country [85] 0 0
Germany
State/province [85] 0 0
Rüdersdorf
Country [86] 0 0
Hungary
State/province [86] 0 0
Gödöllö
Country [87] 0 0
Italy
State/province [87] 0 0
Ancona
Country [88] 0 0
Italy
State/province [88] 0 0
Catania
Country [89] 0 0
Italy
State/province [89] 0 0
Ferrara
Country [90] 0 0
Italy
State/province [90] 0 0
Firenze
Country [91] 0 0
Italy
State/province [91] 0 0
Foggia
Country [92] 0 0
Italy
State/province [92] 0 0
Modena
Country [93] 0 0
Italy
State/province [93] 0 0
Palermo
Country [94] 0 0
Italy
State/province [94] 0 0
Pisa
Country [95] 0 0
Italy
State/province [95] 0 0
Reggio Emilia
Country [96] 0 0
Italy
State/province [96] 0 0
Torino
Country [97] 0 0
Japan
State/province [97] 0 0
Akashi-Shi
Country [98] 0 0
Japan
State/province [98] 0 0
Asahikawa-Shi
Country [99] 0 0
Japan
State/province [99] 0 0
Chiyoda-Ku
Country [100] 0 0
Japan
State/province [100] 0 0
Chuo-Ku
Country [101] 0 0
Japan
State/province [101] 0 0
Fukui-Shi
Country [102] 0 0
Japan
State/province [102] 0 0
Fukuoka-Shi
Country [103] 0 0
Japan
State/province [103] 0 0
Fukuyama-Shi
Country [104] 0 0
Japan
State/province [104] 0 0
Habikino-Shi
Country [105] 0 0
Japan
State/province [105] 0 0
Higashiosaka-Shi
Country [106] 0 0
Japan
State/province [106] 0 0
Himeji-Shi
Country [107] 0 0
Japan
State/province [107] 0 0
Hiroshima-Shi
Country [108] 0 0
Japan
State/province [108] 0 0
Iizuka-Shi
Country [109] 0 0
Japan
State/province [109] 0 0
Isesaki-Shi
Country [110] 0 0
Japan
State/province [110] 0 0
Itabashi-Ku
Country [111] 0 0
Japan
State/province [111] 0 0
Kagoshima-Shi
Country [112] 0 0
Japan
State/province [112] 0 0
Kanazawa-Shi
Country [113] 0 0
Japan
State/province [113] 0 0
Kasuga-Shi
Country [114] 0 0
Japan
State/province [114] 0 0
Kawaguchi-Shi
Country [115] 0 0
Japan
State/province [115] 0 0
Kishiwada-Shi
Country [116] 0 0
Japan
State/province [116] 0 0
Kobe-Shi
Country [117] 0 0
Japan
State/province [117] 0 0
Kodaira-Shi
Country [118] 0 0
Japan
State/province [118] 0 0
Kokubunji-Shi
Country [119] 0 0
Japan
State/province [119] 0 0
Koshi-Shi
Country [120] 0 0
Japan
State/province [120] 0 0
Koshigaya-Shi
Country [121] 0 0
Japan
State/province [121] 0 0
Kurashiki-Shi
Country [122] 0 0
Japan
State/province [122] 0 0
Kyoto-Shi
Country [123] 0 0
Japan
State/province [123] 0 0
Machida-Shi
Country [124] 0 0
Japan
State/province [124] 0 0
Matsuyama-Shi
Country [125] 0 0
Japan
State/province [125] 0 0
Mibu
Country [126] 0 0
Japan
State/province [126] 0 0
Minato-Ku
Country [127] 0 0
Japan
State/province [127] 0 0
Mizunami-Shi
Country [128] 0 0
Japan
State/province [128] 0 0
Muroran-Shi
Country [129] 0 0
Japan
State/province [129] 0 0
Nagakute-Shi
Country [130] 0 0
Japan
State/province [130] 0 0
Nagoya-Shi
Country [131] 0 0
Japan
State/province [131] 0 0
Naka-Gun
Country [132] 0 0
Japan
State/province [132] 0 0
Nakano-Ku
Country [133] 0 0
Japan
State/province [133] 0 0
Naruto-Shi
Country [134] 0 0
Japan
State/province [134] 0 0
Obihiro-Shi
Country [135] 0 0
Japan
State/province [135] 0 0
Ome-Shi
Country [136] 0 0
Japan
State/province [136] 0 0
Osaka Sayama-Shi
Country [137] 0 0
Japan
State/province [137] 0 0
Osaki-Shi
Country [138] 0 0
Japan
State/province [138] 0 0
Ota-Ku
Country [139] 0 0
Japan
State/province [139] 0 0
Ota-Shi
Country [140] 0 0
Japan
State/province [140] 0 0
Oura-Gun
Country [141] 0 0
Japan
State/province [141] 0 0
Sagamihara-Shi
Country [142] 0 0
Japan
State/province [142] 0 0
Sapporo-Shi
Country [143] 0 0
Japan
State/province [143] 0 0
Seto-Shi
Country [144] 0 0
Japan
State/province [144] 0 0
Shibuya-Ku
Country [145] 0 0
Japan
State/province [145] 0 0
Shinagawa-Ku
Country [146] 0 0
Japan
State/province [146] 0 0
Shinjuku-Ku
Country [147] 0 0
Japan
State/province [147] 0 0
Sumida-Ku
Country [148] 0 0
Japan
State/province [148] 0 0
Tachikawa-Shi
Country [149] 0 0
Japan
State/province [149] 0 0
Tokyo
Country [150] 0 0
Japan
State/province [150] 0 0
Tomakomai-Shi
Country [151] 0 0
Japan
State/province [151] 0 0
Tsu-Shi
Country [152] 0 0
Japan
State/province [152] 0 0
Uozu-Shi
Country [153] 0 0
Japan
State/province [153] 0 0
Urasoe-Shi
Country [154] 0 0
Japan
State/province [154] 0 0
Uruma-Shi
Country [155] 0 0
Japan
State/province [155] 0 0
Wakayama-Shi
Country [156] 0 0
Japan
State/province [156] 0 0
Yokohama-Shi
Country [157] 0 0
Japan
State/province [157] 0 0
Yonago-Shi
Country [158] 0 0
Korea, Republic of
State/province [158] 0 0
Bucheon-Si
Country [159] 0 0
Korea, Republic of
State/province [159] 0 0
Busan
Country [160] 0 0
Korea, Republic of
State/province [160] 0 0
Cheongju-Si
Country [161] 0 0
Korea, Republic of
State/province [161] 0 0
Incheon
Country [162] 0 0
Korea, Republic of
State/province [162] 0 0
Seoul
Country [163] 0 0
Korea, Republic of
State/province [163] 0 0
Suwon
Country [164] 0 0
Korea, Republic of
State/province [164] 0 0
Uijeongbu-Si
Country [165] 0 0
Mexico
State/province [165] 0 0
Chihuahua
Country [166] 0 0
Mexico
State/province [166] 0 0
Cuautitlan Izcalli
Country [167] 0 0
Mexico
State/province [167] 0 0
Durango
Country [168] 0 0
Mexico
State/province [168] 0 0
Guadalajara
Country [169] 0 0
Mexico
State/province [169] 0 0
Mexico City
Country [170] 0 0
Mexico
State/province [170] 0 0
Monterrey
Country [171] 0 0
Mexico
State/province [171] 0 0
México
Country [172] 0 0
Mexico
State/province [172] 0 0
San Juan Del Rio
Country [173] 0 0
Mexico
State/province [173] 0 0
Veracruz
Country [174] 0 0
Mexico
State/province [174] 0 0
Zapopan
Country [175] 0 0
Poland
State/province [175] 0 0
Bialystok
Country [176] 0 0
Poland
State/province [176] 0 0
Gdansk
Country [177] 0 0
Poland
State/province [177] 0 0
Krakow
Country [178] 0 0
Poland
State/province [178] 0 0
Lodz
Country [179] 0 0
Poland
State/province [179] 0 0
Poznan
Country [180] 0 0
Poland
State/province [180] 0 0
Sopot
Country [181] 0 0
Poland
State/province [181] 0 0
Strzelce Opolskie
Country [182] 0 0
Russian Federation
State/province [182] 0 0
Ekaterinburg
Country [183] 0 0
Russian Federation
State/province [183] 0 0
Moscow
Country [184] 0 0
Russian Federation
State/province [184] 0 0
Ryazan
Country [185] 0 0
Russian Federation
State/province [185] 0 0
Saint-Petersburg
Country [186] 0 0
Russian Federation
State/province [186] 0 0
St-Petersburg
Country [187] 0 0
Russian Federation
State/province [187] 0 0
Yaroslavl
Country [188] 0 0
South Africa
State/province [188] 0 0
Brandfort
Country [189] 0 0
South Africa
State/province [189] 0 0
Cape Town
Country [190] 0 0
South Africa
State/province [190] 0 0
Durban
Country [191] 0 0
South Africa
State/province [191] 0 0
Pretoria
Country [192] 0 0
Spain
State/province [192] 0 0
Barcelona
Country [193] 0 0
Spain
State/province [193] 0 0
Palma De Mallorca
Country [194] 0 0
Spain
State/province [194] 0 0
Pozuelo De Alarcón
Country [195] 0 0
Spain
State/province [195] 0 0
Sant Boi De Llobregat
Country [196] 0 0
Spain
State/province [196] 0 0
Santiago De Compostela
Country [197] 0 0
Spain
State/province [197] 0 0
Sevilla
Country [198] 0 0
Spain
State/province [198] 0 0
Valencia
Country [199] 0 0
Taiwan
State/province [199] 0 0
Kaohsiung
Country [200] 0 0
Taiwan
State/province [200] 0 0
New Taipei City
Country [201] 0 0
Taiwan
State/province [201] 0 0
Taichung
Country [202] 0 0
Taiwan
State/province [202] 0 0
Taipei
Country [203] 0 0
Taiwan
State/province [203] 0 0
Taoyuan
Country [204] 0 0
Turkey
State/province [204] 0 0
Ankara
Country [205] 0 0
Turkey
State/province [205] 0 0
Bursa
Country [206] 0 0
Turkey
State/province [206] 0 0
Istanbul
Country [207] 0 0
Turkey
State/province [207] 0 0
Izmir
Country [208] 0 0
Turkey
State/province [208] 0 0
Kirikkale
Country [209] 0 0
Turkey
State/province [209] 0 0
Kocaeli
Country [210] 0 0
Turkey
State/province [210] 0 0
Mersin
Country [211] 0 0
Turkey
State/province [211] 0 0
Rize
Country [212] 0 0
Ukraine
State/province [212] 0 0
Chernivtsi
Country [213] 0 0
Ukraine
State/province [213] 0 0
Dnipro
Country [214] 0 0
Ukraine
State/province [214] 0 0
Ivano-Frankivsk
Country [215] 0 0
Ukraine
State/province [215] 0 0
Kharkiv
Country [216] 0 0
Ukraine
State/province [216] 0 0
Kyiv
Country [217] 0 0
Ukraine
State/province [217] 0 0
Odessa
Country [218] 0 0
Ukraine
State/province [218] 0 0
Poltava
Country [219] 0 0
Ukraine
State/province [219] 0 0
Ternopil
Country [220] 0 0
Ukraine
State/province [220] 0 0
Vinnytsya
Country [221] 0 0
Ukraine
State/province [221] 0 0
Zaporizhia
Country [222] 0 0
United Kingdom
State/province [222] 0 0
Bradford
Country [223] 0 0
United Kingdom
State/province [223] 0 0
London
Country [224] 0 0
United Kingdom
State/province [224] 0 0
Newcastle Upon Tyne
Country [225] 0 0
United Kingdom
State/province [225] 0 0
Portsmouth
Country [226] 0 0
United Kingdom
State/province [226] 0 0
South Shields
Country [227] 0 0
United Kingdom
State/province [227] 0 0
Sutton-In-Ashfield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Regeneron Pharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent
asthma.

Secondary Objectives:

- To evaluate the safety and tolerability of dupilumab.

- To evaluate the effect of dupilumab on improving participant-reported outcomes including
health-related quality of life.

- To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Trial website
https://clinicaltrials.gov/show/NCT02414854
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications